Utility of PREDICT-HF score in high-risk Asian heart failure patients receiving sacubitril/valsartan

Hsu, Cheng Chen; Chang, Hung‐Yu; Chao, Chieh‐Ju; Chiou, Wei‐Ru; Lin, Po-Lin; Chung, Fa‐Po; Lin, Wea‐Lung; Huang, Jin‐Long; Liang, Huai‐Wen; Liao, Chia‐Te; Lee, Ying‐Hsiang

doi:10.3389/fcvm.2022.950389

Cited by 5 publications

(3 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Various studies reported the discontinuation of Sacubitril/Valsartan therapy due to side effects, such as hypotension and hyperkalemia. 24 However, none of the patients discontinued therapy because of hypotension in the current study as only a few patients (<5%) reported hypotension in the current study.…”

Section: Discussionmentioning

confidence: 54%

Effectiveness and Safety of Sacubitril/Valsartan in Heart Failure in India: A Retrospective Real-world (SAVE) Study

Sachdeva,

Shukla,

Mayabhate

et al. 2024

Indian Journal of Clinical Cardiology

View full text Add to dashboard Cite

Background: Sacubitril/Valsartan is one of the pillars of heart failure (HF) management. Little is known about its uses or impact in real-world practice in the Indian population. We evaluated the effectiveness and Safety of Sacubitril/Valsartan in Heart Failure in India. Methods: This retrospective analysis involved newly diagnosed adult patients of HF (class I–IV, per physician clinical assessment and discretion), treated in a tertiary care hospital during period of February–April 2023 and received Sacubitril/Valsartan. N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels were measured in addition to demographics, clinical symptoms, comorbidities, and left ventricular ejection fraction (LVEF). Following three months of Sacubitril/Valsartan medication, changes in LVEF, NT-proBNP levels, and clinical symptoms (graded from 1 to 10, with 10 being the maximum severity) were assessed. Results: Out of 60 patients eligible for the study, 57% were males and 43% were females. Mean body weight was 60.26 ± 7.00 kg, while mean BP was 130/81 mmHg. 60% patients had both type 2 diabetes and hypertension as comorbidity. There was 23% improvement in LVEF (from mean LVEF of 34 to 42, P < .0001), with a significant decrease in NT-proBNP levels (mean 1220.5 pg/mL to 118.1 pg/mL, P < .0001) after treatment with Sacubitril/Valsartan for 3 months, resulted in marked improvement in clinical symptoms of breathlessness (mean score decreased from 6 to 2, P < .05), edema (mean score decreased from 5.5 to 1.8, P < .05) and palpitations (mean score decreased from 2.4 to 1.1, P < .05. 50 mg BD was the most commonly used dose of Sacubitril/Valsartan (70% patients), followed by 100 mg BD (25% patients) and rest (5%) with 200 mg BD dose. Treatment with Sacubitril/Valsartan was well tolerated, with <5% patients reporting hypotension. Conclusion: The findings of this real-world study suggest Sacubitril/Valsartan was associated with an increase in ejection fraction translating into symptomatic improvement in Indian patients of HF.

show abstract

Section: Discussionmentioning

confidence: 54%

Effectiveness and Safety of Sacubitril/Valsartan in Heart Failure in India: A Retrospective Real-world (SAVE) Study

Sachdeva,

Shukla,

Mayabhate

et al. 2024

Indian Journal of Clinical Cardiology

View full text Add to dashboard Cite

show abstract

“…A multivariable Cox proportional hazards model was computed to assess the factors associated with reaching the vericiguat maximal daily dose at any given time over the 90 days of follow-up. The model included the time to reach the maximal daily dose during the 90 days of follow-up as the outcome and was adjusted for known predictors of HF medication uptitration [ 26 , 27 ], such as age, sex, comorbidities, and the use of HF medications and non-pharmacological therapies. The model computed hazard ratios (HRs) with 95% confidence intervals (CIs) for each variable included.…”

Section: Methodsmentioning

confidence: 99%

Vericiguat Use in Patients with Heart Failure in Real-World Settings during the First Year after the Drug Authorization in Japan

Okami,

Ohlmeier,

Takeichi

et al. 2024

JCM

View full text Add to dashboard Cite

Background: Vericiguat was developed to treat patients with heart failure (HF). Currently, limited data are available to characterize vericiguat-treated patients in real-world clinical settings. Methods: This retrospective cohort study was done using a Japanese hospital administrative database to describe the use of vericiguat in patients with HF in real-world settings. Adult patients diagnosed with HF prescribed vericiguat between 1 July 2021 and 30 September 2022 were included. Patient characteristics at the initiation of vericiguat treatment, patterns of HF medication use, and vericiguat dose titrations were assessed within the first 90 days of treatment. Results: The study included 829 patients who were initiated on vericiguat therapy. The mean age was 75.5 years and 69.0% were male. Hypertension, coronary artery disease, and diabetes mellitus were present in 91.7, 71.3, and 60.1% of patients, respectively. Most patients had previously received HF medications, with high percentages using angiotensin-receptor blocker neprilysin inhibitors (ARNI; 43.9%) and sodium-glucose cotransporter-2 inhibitors (54.4%). During the first 90 days of vericiguat treatment, 65.8% of the patients were uptitrated from their starting dose, and 32.3% had reached the maximal daily dose. The median time to reach the maximal daily dose was 34 days. The multivariable model identified that initiating vericiguat treatment in an outpatient setting and using ARNI before initiating vericiguat treatment were factors significantly associated with reaching the maximal daily dose of vericiguat at any given time, whereas older age, chronic kidney disease, hyperkalemia, and anemia were not associated. Conclusions: These findings provide early insights into the use of vericiguat, which aid in optimizing the combinations and/or sequences of HF treatment incorporating vericiguat therapy.

show abstract

“…(1) Taiwan Society of Cardiology-Heart Failure Registry with Reduced Ejection Fraction Registry, 10 which is a prospective multicenter observational survey of patients with HFrEF recently admitted for HF in 21 hospitals from 2013 to 2014. (2) The Treatment with angiotensin receptor neprilysin inhibitor for Taiwan Heart Failure patient study, 11,12 which was a principal investigator-initiated multicenter retrospective HFrEF study that recruited symptomatic patients with HFrEF from 10 hospitals from 2017 to 2018.…”

Section: Study Design and Patient Characteristicsmentioning

confidence: 99%

Iron deficiency in Taiwanese patients with heart failure and reduced ejection fraction

Sung

Hsu

Lee

et al. 2023

Journal of the Chinese Medical Association

Self Cite

View full text Add to dashboard Cite

Background: Iron deficiency (ID) is a common comorbidity among patients with heart failure and reduced ejection fraction (HFrEF), and is associated with poorer outcomes independent of anemia. This study aimed to evaluate the prevalence and prognostic significance of ID in Taiwanese patients with HFrEF. Methods: We included HFrEF patients from two multicenter cohorts at different periods. The multivariate Cox regression analysis was applied to assess the risk of outcomes associated with ID, accounting for the varying risk of death. Results: Of the 3612 patients with HFrEF registered from 2013 to 2018, 665 patients (18.4%) had available baseline iron profile measurements. Of these, 290 patients (43.6%) were iron deficient; 20.2% had ID+/anemia+, 23.4% ID+/anemia−, 21.5% ID−/anemia+, and 34.9% ID−/anemia−. Regardless of anemia status, patients with coexisting ID had a higher risk than those without ID (all-cause mortality: 14.3 vs 9.5 per 100 patient-years, adjusted hazard ratio [HR] 1.33; 95% confidence interval [CI], 0.96-1.85; p = 0.091; cardiovascular mortality: 10.5 per 100 patient-years vs 6.1, adjusted HR 1.54 [95% CI, 1.03-2.30; p = 0.037]; cardiovascular mortality or first unplanned hospitalization for HF: 36.7 vs 19.7 per 100 patient-years, adjusted HR 1.57 [95% CI, 1.22-2.01; p < 0.001]). Among patients eligible for treatment in the IRONMAN trial design (43.9%), parenteral iron therapy was estimated to reduce heart failure hospitalizations and cardiovascular deaths by 13.7 per 100 patient-years. Conclusion: Iron profiles were tested in less than one-fifth of the Taiwanese HFrEF cohort. ID was present in 43.6% of tested patients and was independently associated with poor prognosis in these patients.

show abstract

Utility of PREDICT-HF score in high-risk Asian heart failure patients receiving sacubitril/valsartan

Cited by 5 publications

References 27 publications

Effectiveness and Safety of Sacubitril/Valsartan in Heart Failure in India: A Retrospective Real-world (SAVE) Study

Effectiveness and Safety of Sacubitril/Valsartan in Heart Failure in India: A Retrospective Real-world (SAVE) Study

Vericiguat Use in Patients with Heart Failure in Real-World Settings during the First Year after the Drug Authorization in Japan

Iron deficiency in Taiwanese patients with heart failure and reduced ejection fraction

Contact Info

Product

Resources

About